IN THIS ISSUE Progenity $1.79 Possible short squeeze ahead, alongside strong disruptive technology in the medical field. Look at my last...

IN THIS ISSUE Progenity This small biotechnology company has fallen from $15 a share to $1 a share in one year. We think this can go to...

IN THIS ISSUE Progenity This company is developing groundbreaking medical technology. Learn why we think now is a good time to buy....

Please subscribe to us, we are worth your time and will keep you informed! RECAP OF LAST WEEK AND RESULTS: Cassava Sciences This company...